Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Pharmacogenetics of insulin secretagogue antidiabetics].

Orvosi hetilap - 9 Oct 2011

Winkler Gábor, Gerô László

Abstract excerpt

Type 2 diabetes is making up to 90% of the all diabetic cases. In addition to insulin resistance, insufficient B-cell function also plays an important role in the pathogenesis of the disease. The insufficient production and secretion of insulin can be increased by secretagogue drugs, like sulfonylureas and incretin mimetics/enhancers. In recent years growing number of genetic failures of the B-cells has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glucagon-Like Peptide 1
Share to Hypoglycemic Agents
Share to Insulin Secretion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KATP Channels

Share to Potassium Channels, Inwardly Rectifying

Share to Receptors, Drug

Share to Sulfonylurea Compounds

Share to Sulfonylurea Receptors

Source

Identifiers

PMID: 21959939
DOI: 10.1556/OH.2011.29175

Genes

ABCC8
KCNJ11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Pharmacogenetics of insulin secretagogue antidiabetics].PMID 21959939Read ↗

Genetics of type 2 diabetes mellitus and other specific types of diabetes; its role in treatment modalities.Semantic proximity Read ↗

ABCC8 genetic variants and risk of diabetes mellitus.Semantic proximity Read ↗

Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.Semantic proximity Read ↗

Pharmacogenetics of Type 2 Diabetes—Progress and ProspectsSemantic proximity Read ↗

Sulfonylurea receptor -1 (SUR1): genetic and metabolic evidences for a role in the susceptibility to type 2 diabetes mellitus.Semantic proximity Read ↗

Pharmacogenetics of Oral Antidiabetic DrugsSemantic proximity Read ↗

KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Semantic proximity Read ↗

Ion Transporters, Channelopathies, and Glucose DisordersSemantic proximity Read ↗

[Genetic basis of impaired insulin secretion, insulin resistance, the clinical picture and treatment of type 2 diabetes].Semantic proximity Read ↗

[Pharmacogenetics of oral antidiabetic treatment].Semantic proximity Read ↗

Clinical and Genetic Characteristics of ABCC8 Nonneonatal Diabetes Mellitus: A Systematic Review.Semantic proximity Read ↗

Combined risk allele score of eight type 2 diabetes genes is associated with reduced first-phase glucose-stimulated insulin secretion during hyperglycemic clamps.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.